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AbstrAct
Renal ischemia-reperfusion (rI/R) could cause remote acute lung injury (ALI) 
and combination of these two organ injuries can remarkably increase the mortality. 
This study aims to determine whether dexmedetomidine, an α2-adrenoreceptor 
agonist sedative, can ameliorate pulmonary microvascular hyper-permeability 
following rI/R injury and explore the underlying mechanisms. In vivo, C57BL/6J 
mice received dexmedetomidine (25µg/kg, i.p.) in the absence or presence of α2-
adrenergic antagonist atipamezole (250µg/kg, i.p.) or focal adhesion kinase (FAK) 
inhibitor (30mg/kg, i.p.) before bilateral renal pedicle clamping for 45 minutes 
followed by 24 hours reperfusion. The lung histopathological changes and the 
permeability of pulmonary microvascular were assessed respectively. In vitro, the 
cultured C57BL/6J mice pulmonary microvascular endothelial cells (PMVECs) were 
treated with serum from mice with rI/R with or without dexmedetomidine and 
atipamezole. Trans-endothelial permeability and phospho-tyrosine397FAK, F-actin, 
VE-cadherin and ZO-1 in monolayer PMVECs were measured respectively in the 
presence or absence of rI/R serum, dexmedetomidine and FAK inhibitor. In vivo, 
dexmedetomidine remarkably attenuated lung injury and pulmonary microvascular 
hyper-permeability caused by rI/R injury, which was abolished by atipamezole or FAK 
inhibitor co-administration. In vitro, the permeability of PMVECs monolayer following 
exposure to serum from rI/R mice was increased significantly, and decreased by 
dexmedetomidine. Dexmedetomidine increased phospho-tyrosine397FAK in a time- and 
dose-dependent manner, which was correlated with the changes in trans-endothelial 
permeability. Our data indicated that dexmedetomidine is able to ameliorate remote 
pulmonary microvascular hyper-permeability induced by rI/R, at least in part, via 
FAK modulation. 
IntroductIon
Acute kidney injury (AKI) is a frequent complication 
amongst the critical ill patients especially following major 
cardiovascular surgery [1-3]. Previous accumulated 
studies have demonstrated that AKI induced by ischemia/
reperfusion (I/R) leads to dysfunction of the extra-renal 
organs including lung, heart, brain, small intestine and 
liver [4-7]. Due to its large microcapillary network, the 
lung is highly susceptible to damage caused by circulating 
pro-inflammatory or pro-apoptosis mediators from kidney 
inflicted with I/R [8]. The mortality of combined AKI and 
acute lung injury (ALI) even reaches up to 80% in critical 
care settings [9].
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Pulmonary microvascular endothelial cells 
(PMVECs) are important to maintain the homeostasis 
of pulmonary and cardiovascular systems. The various 
circulating mediators produced following AKI might 
directly activate the pulmonary signaling pathways, 
including pro-inflammatory, pro-apoptotic and vascular-
reaction responses in the lung. Lung edema from 
pulmonary microvascular endothelial barrier disruption is 
one of the hallmark features of ALI. Hence, maintenance 
and repair of PMVECs barrier might become an effective 
treatment strategy for AKI-induced ALI.
Dexmedetomidine is a highly selective α2-
adrenoreceptor agonist with sedative, analgesic, 
sympatholytic, hemodynamic stabilizing and diuretic 
properties, and it has been widely used in the operating 
rooms and intensive care units (ICU) [10]. Recent studies 
[11-15], either in vivo or in vitro, demonstrated that 
dexmedetomidine exerted potential protective effects 
against lung, kidney, brain, intestine and heart injuries 
induced by I/R injury or other insults. Our previous 
study even demonstrated that pre- or post-treatment with 
dexmedetomidine remarkably attenuated renal ischemia/
reperfusion (rI/R)-associated pulmonary edema through 
its potential anti-inflammatory property [8]. Additionally, 
dexmedetomidine has been reported to activate the neural 
focal adhesion kinase (FAK) [16], a cytoplasmic protein 
tyrosine kinase that plays a central role in initiating 
and integrating various signaling pathways to affect 
F-actin and several crucial proteins that tightly seal 
adjacent endothelial cells, e.g. zonula occludens-1 (ZO-
1) and vascular-endothelial cadherin (VE-cadherin). 
Such proteins are important to maintain the vascular 
barrier integrity and restrict paracellular permeability 
[17, 18]. The present study investigates the hypothesis 
that dexmedetomidine decreases microvascular hyper-
permeability via endothelial FAK signaling to preserve 
PMVECs morphology and function, and ultimately 
protects the lungs, when distant AKI occurs.
results
dexmedetomidine prevents rI/r induced lung 
injury in vivo
Whilst the alveolar structures were integral, 
without any erythrocytes exudation in the Control, 
dexmedetomidine-treated or Sham group (Figure 1Aa, 
b and c), pulmonary structure was almost completely 
damaged in the rI/R groups (Figure 1Ad), with 
remarkable cell infiltration and significant erythrocytes 
leak into alveolar space. Intraperitoneal injection of 
dexmedetomidine at 25 μg/kg before or after rI/R 
significantly reduced the lung injury and erythrocytes 
leakage (Figure 1Ae and 1Af). Co-treatment with the α2-
adrenoceptor antagonist atipamezole or FAK inhibitor 14 
abolished the effect of dexmedetomidine (Figure 1Ag and 
1Ah). All these were corroborated with the mean pattern 
changes in the various groups (Figure 1B). 
Regarding pulmonary microvascular permeability, 
compared to the control group (12.43 ± 0.86 μg), the 
FITC-Albumin extravasation in the rI/R group was 
significantly increased (26.35 ± 1.66 μg) (p < 0.01). Pre-
and post-treatment with dexmedetomidine resulted in 
26% (19.43 ± 2.97 μg, p < 0.05) and 15% (22.36 ± 2.03 
μg, p < 0.05) respective reductions of the leak of FITC-
Albumin when compared that in the rI/R group. Its effect 
was abolished by α2-adrenoceptor antagonist atipamezole 
(24.54 ± 2.42 μg; vs. control, p < 0.05) or FAK inhibitor 
14 (34.4 ± 4.25 μg; vs. control, p < 0.05), suggesting 
dexmedetomidine confers protection to lung via α2-
adrenoceptor or FAK pathway.
dexmedetomidine reduced the hyper-permeability 
of PMVecs monolayer treated with rI/r serum
The permeability coefficient (Pc) of PMVECs 
monolayer treated with 20% rI/R serum continued to 
increase remarkably from 3 hours (Pc = 2.7 ± 0.2 × 10−5 
cm/s vs. control, p < 0.05) to 24 hours (Pc = 4.97 ± 0.15 
× 10−5 cm/s, vs. control, p < 0.001). The Pc of 10% rI/R 
serum treated group increased to 3.27 ± 0.31 × 10−5 cm/s 
(vs. control, p < 0.05; vs. 5% rI/R serum, p < 0.05) at 12 
hours and reached a plateau. Though 5% rI/R serum also 
increased Pc when compared to that of normal serum 
treated group, the increase was not significant (Figure 
2A). Therefore, 20% rI/R serum was used in the following 
experiments. 
Compared to the control group (Pc = 1.88 ± 0.07 
× 10−5 cm/s), the Pc of rI/R serum treated group was 
increased by 2.47 fold (Pc = 4.84 ± 0.13 × 10−5 cm/s, 
p < 0.001). Interestingly, dexmedetomidine treatment 
to 20% rI/R serum induced endothelial barrier hyper-
permeability produced dose-dependent, bidirectional 
changes. The permeability of dexmedetomidine-treated 
groups fell at concentrations ranged 0.001 to 0.1 μM, 
however permeability rose when at higher concentration 
between 0.1 and 10 μM. The PMVECs monolayer hyper-
permeability was attenuated by 18.9% and 17.7% from 
0.01 μM (Pc = 3.89 ± 0.17 × 10−5 cm/s;vs. control, p < 
0.01; vs. 20% rI/R serum, p < 0.01) and 0.1μM (Pc = 3.98 
± 0.18 × 10−5 cm/s; vs. control, p < 0.01; vs. 20% rI/R 
serum, p < 0.01) dexmedetomidine, respectively (Figure 
2B). 
FAK activity in PMVecs in the presence of 
dexmedetomidine
0.1 μM dexmedetomidine led to a linear increase 
in FAK phosphorylation between 1 and 5 minutes. The 
Oncotarget55992www.impactjournals.com/oncotarget
amount of P-Tyr397FAK declined to the baseline at 10 
minutes (Figure 3A and 3B). In PMVECs, P-Tyr397FAK 
molecules were distributed across the cells in a punctuated, 
dot-like pattern, with a preferable localization at the cell 
surface. 
In western blot study, dexmedetomidine resulted 
in a concentration-dependent increase in expression 
of P-Tyr397FAK in PMVECs and its phosphorylated 
level nearly peaked, when normalized to total FAK 
expression, with dexmedetomidine at 0.1 μM. In contrast, 
dexmedetomidine did not significantly increase the 
expression of total FAK (Figure 3C and 3D).
FAK activation reduced the hyper-permeability 
induced by rI/r serum
The FITC-Albumin fluorescence intensity increased 
gradually from 10 minutes and peaked at 60 minutes with 
3.48-fold increase with 20% rI/R serum compared to that 
in the control (p < 0.001). Dexmedetomidine pretreatment 
significantly decreased the permeability of the PMVECs 
monolayer exposed to rI/R serum. Pretreatment with 
FAK inhibitor 14 for 3 hours reversed the permeability 
reduction of monolayer by dexmedetomidine, to imply 
that the mechanism of dexmedetomidine-mediated decline 
in PMVECs monolayer hyper-permeability is likely to 
involve FAK phosphorylation (Figure 4).
Figure 1: dexmedetomidine prevents rI/r induced lung injury and pulmonary microvascular hyper-permeability 
in vivo. C57BL/6J mice were pre-treated or post-treated with dexmedetomidine (Dex) alone or in combination with a2-adrenoceptor 
antagonist atipamezole (Atip) or FAK inhibitor 14 (inhibit FAK phosphorylation)followed by clamping of the bilateral renal pedicle for 45 
minutes and reperfusion 24 hours. A. Example micrographs of lung tissue section under difference conditions (a: Control; b: Dex; c: Sham; 
d:rI/R surgery; e: Pre-Dex + rI/R surgery; f: Post-Dex + rI/R surgery; g: Atip-Dex + rI/R surgery; h: FAK inhibitor-Dex + rI/R surgery; 
Arrows show the erythrocytes); b. Lung injurious scores presented with Box-Whiskers plot; c. The FITC-Albumin extravasation into lung 
tissue. Data are mean ± SD (n = 5-6);*p < 0.05, **p < 0.01, ***p < 0.001vs.Control, #p < 0.05, ##p < 0.05vs.rI/R surgery.
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dexmedetomidine maintains cell cytoskeleton and 
cell junction via FAK activity
The endothelial cell cytoskeleton is a critical 
determinant of vascular integrity and barrier regulation 
and is known to be influenced by FAK [19]. We 
examined the effect of dexmedetomidine and rI/R 
serum on spatial localization and polymerization of 
F-actin by immunofluorescence microscopy. The control 
endothelial cells exhibited a fine central reticular actin 
pattern and there was no visible increase in stress fiber 
formation (Figure 5Aa). Dexmedetomidine treatment 
was associated with rapid and dramatic enhancement of 
polymerized F-actin staining that was spatially confined 
to the cortical cytoskeletal ring, which correlated with 
the enhancement of endothelial barrier function (Figure 
5Ab). Stimulation with 20% rI/R serum for 1 hour 
induced dissolution of the cortical cytoskeleton, and the 
F-actin was prominently organized into axially oriented 
stress fibers in many of the observed cells, to result in 
the appearance of small paracellular gaps (Figure 5Ac). 
Dexmedetomidine pretreatment for 20 minutes before 1 
hour rI/R serum cleared the F-actin in PMVECs from the 
center of the cells to be localized at the cell periphery, to 
diminish the paracellular gaps (Figure 5Ad). The similar 
pattern of actin as of Figure 5Ac appeared when PMVECs 
were treated with FAK inhibitor for 3 hours, followed by 
dexmedetomidine for 20 minutes and 1 hour 20% rI/R 
serum (Figure 5Ae).
The PMVECs constitutively express ZO-1, VE-
cadherin under control conditions and dexmedetomidine 
has no influence on ZO-1 and VE-cadherin baseline 
expressions. 20% rI/R serum led to significant down 
regulation that approximated to 55% in ZO-1 expression 
and 59% in VE-cadherin expression, compared to those 
in the control group (p < 0.01, respectively). Pretreatment 
with dexmedetomidine for 60 minutes significantly 
increased ZO-1 and VE-cadherin expressions by 34% 
and 26%, respectively (vs. 20% rI/R serum, p < 0.01, 
respectively). Pretreatment with FAK inhibitor 14 for 3 
hours reversed dexmedetomidine-associated upregulation 
in ZO-1 and VE-cadherin proteins expressions (vs. control, 
p < 0.01, respectively) (Figure 5B, 5C and D).
dIscussIon
Our work showed that dexmedetomidine ameliorated 
pulmonary microvascular hyper-permeability following 
rI/R and its effect was abolished by α2-adrenoreceptor 
antagonist atipamezole or FAK inhibitor, indicating that 
dexmedetomidine acted in an α2-adrenoreceptor and/or 
FAK-dependent manner. Our in vitro experiments also 
demonstrated that dexmedetomidine improved PMVECs 
barrier function through activation of α2-adrenoreceptor/
FAK pathway, which corresponded to reduction in rI/R 
serum-induced actin stress fiber formation and increase 
in cell junction complex proteins (ZO-1 or VE-cadherin) 
expression.
Pre- and post-treatment with dexmedetomidine at 
25 μg/kg both attenuated FITC-Albumin leaking from 
lung vasculature following rI/R serum stimulation, and 
pre-treatment seemed to be more effective. As previous 
demonstrated, dexmedetomidine possesses potential 
anti-inflammatory and anti-apoptosis properties and 
Figure 2: the effects of rI/r serum on the permeability of PMVecs monolayer and the modulated effects of 
dexmedetomidine on the permeability. The PMVECs monolayer was treated with mice normal serum or different concentrations 
of (5%, 10%, 20%) rI/R serum and their permeability coefficient was assessed; b. 20% rI/R serum was used to test the effects of different 
concentrations (0.001μM~10μM) of dexmedetomidine on the permeability of PMVECs monolayer. Data are expressed as mean ± SD (n = 
4-6); *p < 0.05, **p < 0.01,***p < 0.001vs. Control; #p < 0.05,##p < 0.01,###p < 0.001 vs. 5% rI/R serum; &p < 0.05,&&p < 0.01 vs. 10% rI/R 
serum. ^p < 0.05,^^p < 0.01vs.20% rI/R serum.
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hence provided organ protection [20, 21]. The systematic 
inflammatory responses triggered by inflammatory factors, 
such as tumor necrosis factor-α (TNF-α), interleukin-
1β (IL-1β), IL-6 and macrophage inflammatory 
protein (MIP-1), when released into the circulation 
due to rI/R, can directly damage lung [22]. The anti-
inflammatory effect of dexmedetomidine was proved 
to be an important mechanism of pulmonary protection 
under several pathological conditions including rI/R, 
sepsis and mechanical ventilation [8, 23, 24]. However, 
our current results extend the previous findings to show 
that dexmedetomidine might also provide cyto-protection 
through modulation of F-actin and junctional complex 
proteins, to maintain morphology and function of 
pulmonary microvascular endothelial barrier (Figure 5). 
This is the first study to show that dexmedetomidine can 
provide “local direct” pulmonary protective effects at the 
cellular structure level besides its anti-inflammatory effect 
and beyond. 
The permeability of PMVECs monolayer was 
significantly increased when challenged with different 
concentrations of serum (5%, 10% and 20%) from mice 
underwent rI/R surgery (Figure 2A), which implied 
that “toxicants” including pro-inflammatory mediators 
mentioned above and damage-associated molecular 
pattern molecules (DAPMs), were released from injured 
kidney into circulation to prompt lung damage. Arguably, 
this is robust evidence to indirectly re-confirm our in vivo 
findings. This injury was attenuated by dexmedetomidine 
in a dose-dependent manner (Figure 2B). However, 
Figure3: time-dependent (A and b) and concentration-dependent(c and d) effects of dexmedetomidine on FAK 
phosphorylation of PMVecs. Dexmedetomidine acts in a time-dependent fashion from 1 to 10 minutes and concentration-dependent 
manner from 0.001 to 10μM, promoted the protein expression of P-Tyr397FAK in PMVECs. Data are expressed as the percentage of control 
(mean ± SD, n = 4-6).*p < 0.05, **p < 0.01, ***p < 0.001vs. Control.
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dexmedetomidine at higher concentration (10 μM) lost its 
ability to inhibit rI/R serum induced hyper-permeability of 
PMVECs monolayer. The mechanisms may be involved 
in the activation of other unknown intracellular signals, 
or due to “off-target” signaling through α1-adrenoreceptor 
that remains to be clarified. Interestingly, the bidirectional 
or ceiling effects of dexmedetomidine on the modulation 
of inflammation and cyto-protection has been also 
demonstrated in the previous studies [25, 26]. 
FAK is a highly conserved cytoplasmic tyrosine 
kinase, involved in integrin engagement and focal 
adhesions assembly via its multiple downstream signaling 
pathways [27]. As a key regulator of actin cytoskeleton 
organization, FAK modulates cellular tension transduction, 
from intracellular to extracellular [19]. Furthermore, 
phosphorylated FAK plays a central role in cell adhesion. 
The present study demonstrated that dexmedetomidine 
produced a time- and dose-related FAK phosphorylation 
in PMVECs via α2-adrenoreceptor activation (Figure 3), 
which is consistent with previous report [16, 19]. After 
phosphorylation, FAK can modulate tension signaling 
to control actin and focal adhesion dynamics thus to 
promote adaptive resistance to surrounding environment 
deterioration [19, 28].
FAK has several tyrosine sites such as Y142 
and Y925 besides Y397 [19]. The phosphorylation of 
different tyrosine sites may produce different physiology 
or pathophysiology effects. Inhibition of FAK Y397 
phosphorylation abolished the protective effect of 
dexmedetomidine on endothelial monolayer hyper-
permeability (Figure 4), indicating that dexmedetomidine 
acted cyto-protective effect in a FAK-activity dependent 
manner. 
The endothelial barrier permeability is mainly 
maintained by a balance between the adhesive force 
produced at endothelial cell-cell junctions, and the 
contractile force generated at the endothelial cytoskeleton. 
Previously studies [18, 29] have suggested that junctional 
complexes, such as ZO-1 and VE-cadherin of PMVECs 
are important structures for the maintenance of endothelial 
barrier integrity through focal adhesions between 
endothelia cells and matrix. In many cases [30, 31], 
a complex interplay between cell junctional elements 
and focal adhesions results in rapid actin cytoskeletal 
remodeling. However, under pathological conditions, 
cytoskeletal rearrangement together with various 
Figure 4: the effect of FAK on the rI/r serum induced hyper-permeability of pulmonary endothelial monolayers. 
The endothelial monolayers in transwell chambers were continuously incubated with 10μM FAK inhibitor 14 for 3hours before 0.1μM 
dexmedetomidine treatment for 20 minuets, followed by 20% rI/R serum stimuli for 60 minutes. Fluorescence (FITC-Albumin, 100mg/
mL) was measured at every 10minutes.Data are expressed as mean ± SD (n = 5); *p < 0.05, **p < 0.01,***p < 0.001vs. Control;#p < 0.05,##p 
< 0.01,###p < 0.001vs.20% rI/R serum.
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intracellular signaling that interacts with inflammatory 
cells could promote release of enzymes to breakdown 
pulmonary microvascular endothelial barrier. This leads 
to intercellular gap formation to result in fluid and soluble 
substances moving into lung tissue from blood circulation. 
Fluid overload in the lung due to endothelia barrier 
hyper-permeability ultimately leads to pulmonary edema 
during acute kidney injury [32, 33]. Therefore, protecting 
pulmonary microvascular endothelium integrity may be 
a primary therapeutic strategy for the critical ill patients 
with harmful organ crosstalk exemplified by the current 
case of kidney-lung [34, 35]. When AKI occurs as shown 
in the current study, circulating cytokines accumulate in 
the pulmonary microvasculature to cause cellular F-actin 
rearrangement and junctional complex dissociation, 
and hence increase paracellular permeability. When 
dexmedetomidine binds to the α2-adrenoreceptor, then 
activates FAK with the increased cortical actin ring and 
induces junctional complex assembly that serve to further 
strengthen the endothelial barrier (Figure 6). Collectively, 
our data point to distinct roles for α2-adrenoreceptor/
FAK activity in the control of F-actin and junctional 
complex, both of which are important in the regulation 
of vascular permeability. Interestingly, a previous clinical 
study demonstrated that dexmedetomidine protects 
lungs through anti-oxidative stress mechanisms [36], 
indicating that the pulmonary protection afforded by 
dexmedetomidine reported in the current study is very 
likely due to multiple cellular mechanisms. 
Our work is not without limitations. Firstly, 
circulatory leukocyte adhesion and trafficking play 
an important role in acute lung injury induced by rI/R 
Figure 5: the effects of rI/rserum on F-actin cytoskeletal assembly A., and the ZO-1 and VE-cadherin expressions in PMVECs 
(B,C,D). PMVECs incubated with 10μM FAK inhibitor for 3 hours before 0.1μM dexmedetomidine treatment for 20 minutes, followed 
by 20% rI/R serum stimulation for 60 minutes and F-actin was detected by Immunofluorescence. FITC-phalloidin fluorescence of F-actin 
cytoskeletal assembly with DAPI staining for the nucleus in PMVECs: A. No visible increase in stress fiber formation in the normal cell; 
b. dexmedetomidine significantly enhanced cortical cytoskeleton staining; c. 20% rI/R serum induced dissolution of cortical cytoskeleton 
and formation of prominent stress fiber and intercellular gaps; d. Pretreatment with dexmedetomidine prevented rI/R serum induced actin 
stress fiber formation, and diminished the paracellular gaps ; e. FAK inhibitor reversed the effect of dexmedetomidine. b. ZO-1 and c. 
VE-cadherin were detected by western blot.Data are expressed as the percentage of control (mean ± SD, n = 4);**p < 0.01vs.Control;#p < 
0.05, ##p < 0.01vs.20% rI/R serum.
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[37]. However, their role on pulmonary microvascular 
permeability has not been explored in the present study 
and warrants further study. Secondly, toxic substances and 
water accumulation in the circulation consequent of AKI 
undoubtedly contribute to other organ injury including 
lung injury. Dexmedetomidine can protect kidney injury 
in such type [8, 12] which may also partially indirectly 
attribute its lung protection but yet to be assessed in 
future study. Thirdly, the plasma concentration of 
dexmedetomidine has not been measured in our study. 
By estimation, its concentration in our experimental 
setting is likely much higher than the clinical targeted 
concentration in the plasma [38]. Therefore, it is highly 
plausible that such a high dose could produce pulmonary 
vascular constriction which may contribute to reduction 
in microvascular hyper-permeability. However, one can 
argue in general that an anesthetic drug dose administered 
to animals could be up to > ten times higher than given 
to human [39]. Finally, due to Ethics consideration, 
isoflurane was used for basal anesthesia and it has 
organoprotective effects reported elsewhere. Therefore, 
the pulmonary protective effect of dexmedetomidine found 
in this study could be distorted by the superposed effect 
of isoflurane. However, because of each group of animal 
including the controls all being give this basal anesthesia, 
hence this became not an issue regarding the conclusions 
of the current work. Nevertheless, our study showed that 
serum from kidney I/R mice containing enough injurious 
mediators including cytokines and other mediators are 
sufficient to damage lung cells, indicating that preventing 
primary organ injury is far more important.
In summary, dexmedetomidine attenuates 
pulmonary microvascular hyper-permeability secondary 
to rI/R through up-regulation of phosphorylated FAK 
Figure 6: Putative mechanism of dexmedetomidine-mediated protection of pulmonary endothelial barrier involving 
α2-adrenoreceptor/FAK pathway. In this working model of endothelial barrier regulation, under baseline conditions, a balance exists 
between cytoskeleton contractile and cellular adhesive forces.(Left) When AKI occurs, circulating pro-inflammatory and pro-apoptosis 
mediators transit into pulmonary microvascular, and F-actin was organized into axially oriented stress fibers, with adherens junction 
(AJ) and tight junction (TJ) dissociation, followed by endothelial cells pulling apart to form paracellular gaps to culminate to barrier 
disruption. (Right) Dexmedetomidine binding to α2-adrenoreceptor activates FAK, which exhibits increased tyrosine phosphorylation at 
Y397 site. Phosphorylated FAK subsequently translocates to the endothelial cell periphery where they form new focal contacts associated 
with increased cortical actin ring, to induce junctional complex assembly to strengthen the endothelial barrier. VE-cad, vascular endothelial 
cadherin; ZO-1, zonaoccluden protein-1.
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modulated by α2-adrenoreceptor activation, which are 
likely associated with F-actin modulated endothelial 
intercellular junction complex to facilitate recovery 
following barrier disruption from injurious mediators, e.g. 
cytokines and DAPMS releasing from injured kidney. 
MAterIAls And Methods
In vivo experiments
Animal model
The current study was approved by the Animal 
Care Committee of Third Military Medical University, 
Chong Qing, China, and was performed in accordance 
with the ARRIVE guideline. Male 8- to 10-week-old 
C57BL/6J mice weighing 20 ± 2g were purchased from 
the laboratory animal center of Third Military Medical 
University. Mice were housed in a pathogen-free condition 
at 25 ± 2°C, 55 ± 5% humidity, and a 12 hours light-dark 
cycle, with ad libitum access to standard pellet food and 
sterile water for at least 7 days before experiments. Food 
was removed 8 hours before the operation but free access 
to water was allowed. 
All mice undergoing surgery were anesthetized with 
1.5% isoflurane via mask and their body temperature was 
maintained at 36 ± 0.1°C with a heating pad. Renal I/R 
injury was induced by bilateral renal pedicle clamping 
for 45 minutes and reperfusion for 24 hours to produce 
moderate renal injury as we reported previously [12]. All 
animals received 0.5 ml saline intraperitoneal injection for 
volume supplementary every 6 hours after surgery [12] 
and were sacrificed 24 hours after rI/R. 1ml blood sample 
from abdominal aorta was obtained for each animal with 
or without rI/R injury. The blood was immediately placed 
on ice and then centrifuged (3,000g, 4°C for 15minutes) 
to remove cellular elements. Serum was stored in aliquots 
at -80° C.
Groups and treatments
Animals were randomly allocated into 8 groups (n 
= 5 per group):Control group (Control): no treatment, no 
surgery; Sham group (Sham): laparotomy was performed 
without renal vessels occlusion; Dexmedetomidine 
group (Dex): dexmedetomidine (Precedex® 100μg/ml 
dexmedetomidine, Orion Pharma, Espoo, Finland) at 
25 μg/kg was administered (intraperitoneal) without 
surgery; rI/Rsurgery group (rI/R surgery): laparotomy 
was performed and bilateral renal pedicle clamping 
lasted for 45 minutes, followed by reperfusion for 
24 hours; Dexmedetomidine pretreated group (pre-
Dex): dexmedetomidineat 25 μg/kg (intraperitoneal) 
was administered 15 minutes before rI/R surgery as 
stated above; Dexmedetomidine post-treated group 
(post-Dex): dexmedetomidine at 25 μg/kg was 
administered immediately upon release of bilateral renal 
pedicle clamping; Combination of atipamezole and 
dexmedetomidine group (Atip-Dex): atipamezole(α2-
adrenergic antagonist, Sigma-Aldrich, St. Louis, MO, 
USA) at 250 μg /kg was administered 10 minutes 
prior to dexmedetomidine pre-treatment [12] followed 
by rI/R surgery; Combination of FAK inhibitor and 
dexmedetomidine group (FAK inhibitor-Dex): FAK 
inhibitor 14 (Santa Cruz, CA, USA),an inhibitor FAK 
phosphorylation, was administered at 30 mg/kg 5 minutes 
prior to dexmedetomidine pre-treatment [40] followed by 
renal ischemia surgery. The dose of dexmedetomidine, 
atipamezoleand FAK inhibitor 14 referred to the previous 
established protocols [12, 40].
histopathology assessment
Lung tissues were harvested 24 hours after rI/R 
and embedded in paraffin and sectioned into 5μm 
sections. Sections were stained with hematoxylin/eosin 
and examined under a light microscope. Severity of 
lung injury was evaluated semi-quantitatively using a 
scale system [41] from 0 to 3 grades: Grade 0, normal 
pulmonary histology; Grade 1, mild moderate interstitial 
congestion and neutrophil leukocyte infiltrations; Grade 
2, moderate neutrophil leukocyte infiltration, perivascular 
edema formation, and partial destruction of pulmonary 
architecture; Grade 3, complete destruction of the 
pulmonary architecture with dense neutrophil leukocyte 
infiltrations and abscess formation.
Pulmonary microvascular studies
Pulmonary vascular permeability was quantitatively 
measured by extravasation of FITC-Albumin (Sigma-
Aldrich, St. Louis, MO, USA) into lung parenchyma [42]. 
Briefly, after 22 hours of rI/R, FITC-Albumin 5mg/kg was 
injected via tail vein of mice under surgical anesthesia. 
After 2 hours injection, all mice received thoracotomy 
under terminal anesthesia with 1.5% isoflurane via 
mask, and their lungs were harvested after 10 ml PBS 
transfusion to pulmonary artery for washing intravascular 
blood. The isolated lungs were frozen in liquid nitrogen, 
then homogenized and centrifuged (3,000g, 4°C for 10 
minutes). Supernatant (100μl) was collected and FITC-
Albumin optical density, which indirectly reflects the 
permeability of pulmonary microvascular, was quantitated 
by Varioskan Flash multimode reader (Thermo Fisher 
Scientific, Waltham, MA, USA) at an excitation and 
emission of 494 nm and 520 nm, respectively. The 
assessments were made by an investigator blinded to the 
experimental protocols.
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In vitro experiments
cell culture
C57BL/6J mice pulmonary microvascular 
endothelial cells (PMVECs) were obtained from the Cell 
Biologics Inc. (Chicago, IL, USA). The cells were cultured 
at 37°C and 5% CO2 on gelatin-coated flasks in M-1168 
complete medium as recommended. All experiments 
were performed on early passaged cells (passage3-6) to 
preserve true endothelial cell phenotype.
effects of rI/r serum on PMVecs monolayers 
permeability
PMVECs (1 × 105 cells) were seeded onto polyester 
membranes in the upper chamber of transwell (pore size 
0.4 μm, diameter 6.5 mm, Costar, N.Y. USA) and cultured 
with 0.5ml of M-1168 media. Sufficient media was added 
to each lower chamber to cover the membrane. When cells 
were propagated to 100% confluence, the monolayers 
were exposed to fresh media without phenol red dye and 
FBS for 1 hour, then treated with 20% mice normal serum 
or different concentrations of serum (5%, 10%, 20%) from 
animals underwent rI/R surgery for 24 hours as described 
above. FITC-Albumin (10mg/ml) was added to the upper 
chamber of each transwell for up to 24 hours and 100 μl 
media sample was then collected from the lower chamber 
and their fluorescence were measured at 3, 6, 9, 12, 15, 
18, 21 and 24 hours respectively. Sample readings were 
converted with a standard curve representing the FITC-
Albumin concentration. The permeability coefficient 
(Pc) of FITC-Albumin was determined as previously 
described [43]as Pc = [A]/t × 1/A × V/ [L], where brackets 
denote FITC-albumin concentration in the lower chamber 
[A] or the top chamber [L], t is time (s), A is the area of 
the membrane (cm2), and V is the volume of the lower 
chamber.
effects of dexmedetomidine on the permeability of 
PMVecs monolayer treated with rI/r serum
The optimal concentration (20%) of rI/R serum 
obtained from pilot study as above was used in the 
subsequent experiments. Each of the endothelial 
monolayers in transwell chamber was incubated with 
the fresh culture medium containing dexmedetomidine 
(0.001μM ~ 10μM) for 6 hours, before 24 hours treatment 
with 20% rI/R serum together with FITC-Albumin (10mg/
ml). 100μl sample culture medium was collected from 
the lower chamber and FITC-Albumin was calculated 
by Varioskan Flash multimode reader. The results were 
expressed as percentage of Pc.
effects of dexmedetomidine on FAK activity of 
PMVecs
PMVECs grown on gelatin-coated slips were 
incubated with 0.1μM dexmedetomidine or 20% rI/R 
serum for 1,3, 5 and 10minutes. PMVECs were fixed in 
4% paraformal dehyde for 10 minutes, permeabilized 
with 0.2% Triton X-100 in PBS for 5 minutes, and 
blocked with 2% BSA in PBS for 1 hour. The changes 
in FAK phosphorylation were probed with phospho-
tyrosine397FAK (P-Tyr397FAK) antibody (Abcam, 
Cambridge, MA, USA), and images were captured with 
a Nikon EclipseTE300 inverted microscope (Nikon, 
Tokyo, Japan).Fluorescence intensity of P-Tyr397FAK was 
measured with the Image J software (National Institute of 
Mental Health, Bethesda, Maryland, USA).
The PMVECs were starved from FBS for 1 
hour then incubated with medium containing different 
concentrations of dexmedetomidine(0.001μM ~ 10μM) 
for 5minutes. This duration of incubation was determined 
from preliminary cell immunofluorescence experiment 
as above. It corresponded to the point for which the 
amount of P-Tyr397FAK reached its peak at 5 minutes. 
Proteins were separated by electrophoresis on 10% 
PAGE gels and 5% gradient gels, transferred to PVDF 
membrane (Millipore, Billerica, MA, USA). Membranes 
were blocked for 1 hour with 10% non fat milk in PBS 
containing 0.1% Tween 20. P-Tyr397FAK and FAK Primary 
antibodies (Abcam, Cambridge, MA, USA) were used at 
a concentration of 1:1,000, and HRP-coupled secondary 
antibodies were used at 1:5,000. Immunoblots were 
developed using standard ECL (Millipore, Billerica, MA, 
USA). Data were normalized to standardized to β-actin 
expression, normalized to total FAK expression, and 
expressed as % of control. 
effects of FAK activity on the rI/r serum induced 
PMVecs permeability
The endothelial monolayers in transwell chambers 
were continuously incubated with 10μM FAK inhibitor 
14 for 3hours [40] prior to 0.1μM dexmedetomidine 
treatment for 20 minutes, followed by 20% rI/R serum 
challenge for 60minutes. The control cultures received 
neither treatments. FITC-Albumin (100mg/ml) was 
added in upper chamber at beginning of the treatment and 
100µl sample was collected from the lower chamber to 
measure the real-time changes of permeability across the 
endothelial cell monolayer. The results were expressed as 
FITC-Albuminfluorescence intensity.
cellularF-actin, Zo-1 and Ve-cadherin expression
PMVECs incubated with 10μM FAK inhibitor 14 
for 3 hours before 0.1μM dexmedetomidine treatment for 
20 minutes, followed by 20% rI/R serum for 60 minutes. 
F-actin was visualized by staining cells with FITC-
conjugated phalloidin (Sigma, St. Louis, MO, USA) 
for 1 hour at room temperature. Proteins were extracted 
with cell lysis buffer, and analyzed by SDS-PAGE and 
immunoblots for ZO-1 and VE-cadherin expressions.
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data Analysis
Data were expressed as mean ± SD. One-way 
analysis of variance followed by post hoc Newman-Keuls 
test were used for comparison, otherwise, unpaired two-
tailed Student test were used wherever appropriate. A 
pvalue less than 0.05 was considered to be a statistical 
significance.
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